Economic analysis of the dynamics of procurement of drugs based on monoclonal antibodies and biosimilars: trends and prospects

DOI: https://doi.org/10.29296/25419218-2024-05-04
Issue: 
5
Year: 
2024

A.Yu. Efremov, A.M. Vlasov, D.V. Chugaev, G.V. Ramenskaya, T.M. Litvinova
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University
of the Ministry of Health of the Russian Federation (Sechenov University), Trubetskaya str., 8/2, Moscow, 119991, Russian Federation

Introduction. In recent years, in Russia there has been a tendency to increase the share of domestic biosimilars in the market of monoclonal antibodies (MA), which is associated with government support for domestic manufacturers. Purpose of the study. The purpose of this analysis is to study the market for government procurement of drugs based on MA and its dynamics in 2018–2022. in connection with the emergence of domestic biosimilars. Material and methods. Data from the State Register of Medicines was used to compile a list of all drugs based on MA registered from 2018 to 2022. The analysis of the Russian market was carried out on the basis of the Unified Information System (UIS) of procurement. Purchases of 68 mAb drugs were analyzed, and based on the calculation results, 10 drugs with the largest volume of purchases in monetary terms were identified. Results. Over the five-year period, there was a significant increase in the share of purchases of domestic biosimilars, especially for the drugs Eculizumab, Bevacizumab, Trastuzumab and Rituximab. The share of purchases of domestic biosimilars reached 73% of the total purchase amount. The emergence of domestic biosimilars contributed to a decrease in purchases of imported original drugs. Conclusion. The analysis showed that during the period under study there was a change in market shares in favor of Russian biosimilars. This trend is particularly noticeable for Eculizumab and Bevacizumab. Russian biosimilars occupied a significant market share, which contributed to a decrease in purchases of imported originals.
Keywords: 
biosimilars
government procurement
pharmaceutical market
biosimilars.
References: 
  1. Кирсанова, О.В., Омельяновский В.В., Анализ проблемы регулирования доступа к биосимилярам и пути решения. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2018; 11 (1): 50–5. DOI: 10.17749/2070-4909.2018.11.1.050-055. [Kirsanova O.V., Omelyanovsky V.V., Options to optimize the access to biosimilars: analysis and solutions. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya. 2018; 11 (1): 50–5. DOI: 10.17749/2070-4909.2018.11.1.050-055 (in Russian)]
  2. Трякин А.А., Рудакова А.В., Фогт С.Н. и др. Фармакоэкономические аспекты применения биоаналогов. Современная онкология. 2017; 19 (1): 42–7. DOI: 10.26442/1815-1434_19.1.42-47 [Tryakin A.A., Rudakova A.V., Fogt S.N. et al.. Pharmacoeconomic aspects of biosimilars. Sovremennaya onkologiya. 2017; 19 (1): 42–7. DOI: 10.26442/1815-1434_19.1.42-47 (in Russian)]
  3. Всемирная организация здравоохранения. Официальный сайт [Электронный ресурс]. Режим доступа: https://www.who.int/ru [Official website of the World Health Organization. [Electronic resource]. Available at: https://www.who.int/ru (in Russian)]
  4. Федеральная служба государственной статистики. Официальный сайт [Электронный ресурс]. Режим доступа: https://rosstat.gov.ru/ [Official website of the Federal State Statistics Service. [Electronic resource]. Available at: https://rosstat.gov.ru/ (in Russian)]
  5. Горкавенко Ф.В., Никитина А.В., Сайбель Е.С. и др. Динамика цен и потребления противоопухолевых лекарственных препаратов в сегменте государственных закупок после выхода на российский фармацевтический рынок воспроизведенных препаратов и биоаналогов. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2019; 12 (2): 115–24. DOI: 10.17749/2070-4909.2019.12.2.115-124. [Gorkavenko F.V., Nikitina A.V., Saibel' E.S. et al. Dynamics of prices and consumption of anticancer drugs in Russia after their generics and biosimilars became available. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya. 2019; 12 (2): 115–24. DOI: 10.17749/2070-4909.2019.12.2.115-124 (in Russian)]
  6. Нежникова Е.В., Максимчук М.В. Фармацевтическая отрасль в РФ: проблемы и перспективы развития. Вестник Российского университета дружбы народов. Серия: Экономика. 2019; 27 (1): 102–12. DOI: 10.22363/2313-2329-2019-27-1-102-112. [Nezhnikova E.V., Maksimchuk M.V. Pharmaceutical industry in Russia: problems and prospects of development. Vestnik Rossiiskogo universiteta druzhby narodov. Seriya: Ekonomika. 2019; 27 (1): 102–12. DOI: 10.22363/2313-2329-2019-27-1-102-112 (in Russian)]
  7. Государственный реестр лекарственных средств. Министерство здравоохранения Российской Федерации. [Электронное издание]. Режим доступа: https://grls.minzdrav.gov.ru/default.aspx [Official website of the State Register of Medicines. [Electronic resource]. Available at: https://grls.minzdrav.gov.ru/default.aspx (in Russian)]
  8. Единая информационная система в сфере закупок. [Электронное издание]. Режим доступа: https://zakupki.gov.ru/epz/main/public/home.html [Official website of the Unified Procurement Information System. [Electronic resource]. Available at: https://zakupki.gov.ru/epz/main/public/home.html (in Russian)]
  9. Министерство промышленности и торговли России. Официальный сайт [Электронный ресурс]. Режим доступа: https://minpromtorg.gov.ru/ [Official website of the Ministry of Industry and Trade of Russia. [Electronic resource]. Available at: https://minpromtorg.gov.ru/ (in Russian)]
  10. Григорьева К.Д. Лекарственное импортозамещение – перспективное направление развития российской экономики. Управленческое консультирование. 2018; 5 (113): 137–42. DOI: 10.22394/1726-1139-2018-5-137-142. [Grigor'eva K.D. Drug import replacement is a perspective direction of the development of Russian economy. Upravlencheskoe konsul'tirovanie. 2018; 5 (113): 137–42. DOI: 10.22394/1726-1139-2018-5-137-142 (in Russian)]
  11. Графова Т.О., Яковенко В.А., Кононов А.Н. Импортозамещение и санкционная перестройка отечественной фарминдустрии. Экономические науки. 2023; 229: 485–92. DOI: 10.14451/1.229.485. [Grafova T.O., Yakovenko V.A., Kononov A.N. Import substitution and sanctions restructuring of the domestic pharmaceutical industry. Ekonomicheskie nauki. 2023; 229: 485–92. DOI 10.14451/1.229.485 (in Russian)]